NDC codes

FDA NDC Directory
Product NDC (as listed)73289-0089Labeler and product segments. Claims need a package NDC.
Product NDC at billing width73289-0089Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
73289-0089-1732890089017328900890113 mL in 1 BOTTLE (73289-0089-1)Marketed from Jun 30, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Pyquvi
Generic name (nonproprietary)
deflazacort
Active ingredients
Deflazacort — 22.75 mg/mL
Dosage form
Suspension
Route
Oral
Labeler
Aucta Pharmaceuticals, Inc.NDC labeler code 73289
Product type
Prescription drug
Marketing category
ANDA — Abbreviated New Drug Application (generic)Application ANDA 219417
Marketing start
Listing expires
Other FDA classes
Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers
Product ID 73289-0089_39853cd7-c033-848f-e063-6294a90a49e4SPL ID 39853cd7-c033-848f-e063-6294a90a49e4SPL set ID 39854f19-d8be-6438-e063-6394a90a9422RxCUI 1870964, 2719198UNII KR5YZ6AE4B
Pharmacologic class
Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N473289008901 followed by a unit qualifier and the quantity

Package 73289-0089-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

PYQUVI is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza ® (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. PYQUVI is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 73289-0089

What is NDC 73289-0089?
73289-0089 is the product NDC for Pyquvi (deflazacort), Deflazacort 22.75 mg/mL suspension, listed with the FDA by Aucta Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?
Pyquvi (Deflazacort).
What is the active ingredient?
Deflazacort.
Who is the labeler?
Aucta Pharmaceuticals, Inc., NDC labeler code 73289. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Pyquvi?
None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?
Not in Med-Code's curated HCPCS directory. See Billing references above.

Free account

Log in to keep searching

You’ve used your 3 free searches. Med-Code is free: log in or create a free profile to keep looking up NDCs, J-codes and drugs.

Create a free profileLog in